Compare RXT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | DBVT |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | France |
| Employees | N/A | 161 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2020 | 2014 |
| Metric | RXT | DBVT |
|---|---|---|
| Price | $4.70 | $18.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $1.71 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 27.8M | 174.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.13 | 10.26 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,685,700,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $1.35 | $2,360.78 |
| P/E Ratio | $160.83 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $0.39 | $7.53 |
| 52 Week High | $7.65 | $26.19 |
| Indicator | RXT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 37.63 |
| Support Level | $1.04 | $16.49 |
| Resistance Level | N/A | $21.61 |
| Average True Range (ATR) | 1.03 | 0.83 |
| MACD | 0.19 | -0.13 |
| Stochastic Oscillator | 52.57 | 3.10 |
Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.